Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Hawaii: below-average open trial sites
112 of 437 in-state trials are recruiting (26%); below the 37% national average by 11 percentage points.
According to ClinicalTrials.gov-derived indexes, Hawaii sits in the lower half of US states by in-state trial count (#44 of 52 states by registered in-state trial count).
Hawaii: 437 US clinical trials with in-state sites, 112 recruiting.
Hawaii has 437 registered US clinical trials with a study site in-state, 112 of them currently recruiting (below the 37% national average by 11 percentage points). 137 of these trials are in Phase 3 (late-stage) and 111 in Phase 2. The most frequently studied condition in Hawaii is HIV Infections, with 30 linked trials.
Thin-volume Hawaii archive
Hawaii open-enrollment share is 26% (p8 of states with sites; national baseline 37%). Treat this page as a compact local index (thin-volume · low-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Hawaii still shows 112 recruiting of 437 in-state trials (26% open), but below the 37% national average by 11 percentage points, so archived statuses weigh heavier than the national baseline.
- 26%
- open (below national share)
- 112
- still recruiting despite cool share
- 111
- Phase 2 rows in this footprint
- 30
- top: HIV Infections
Recruiting share is below the 37% national average by 11 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Hawaii vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
437 Top 85% more indexed trials than 15% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Hawaii on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hawaii open-enrollment share sits below the national baseline.
112 of 437 in-state trials (25.6%) are recruiting, against 37% nationally (-11.4 percentage points). Counts include every study with at least one recorded site in the state.
-
Honolulu dominates Hawaii's trial geography.
Honolulu lists 405 of 437 in-state trials (92.7%) across 148 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
HIV Infections is the most-studied condition in Hawaii.
30 of 437 in-state trials (6.9%) list HIV Infections. That is a local concentration figure, not a national disease ranking.
-
Hawaii sponsorship is fragmented across many organizations.
Eli Lilly and Company appears on 28 of 437 in-state trials (6.4%). Sponsor identity is as filed on ClinicalTrials.gov.
-
Most Hawaii indexed trials have already finished enrollment.
219 of 437 (50.1%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 219 |
| Recruiting | 112 |
| Active | 106 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 137 |
| Phase 2 | 111 |
| NA | 97 |
| Phase 1 | 29 |
| Phase 4 | 10 |
| Early Phase 1 | 1 |
Top Conditions
Top Sponsors
Where trials run in Hawaii
Honolulu carries 405 of Hawaii's 437 indexed trials (93%) across 148 named sites, ahead of ‘Aiea at 27. 6 cities clear five listed trials, together naming 179 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Honolulu | 405 | 148 |
| ‘Aiea | 27 | 18 |
| Tripler AMC | 7 | 3 |
| Kailua | 7 | 5 |
| ‘Ewa Beach | 5 | 3 |
| Lihue | 5 | 2 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Hawaii open-enrollment share is 26% (p8 of states with sites; national baseline 37%).
Hawaii: open share sits in the low tercile of states
Geography is concentrated: Honolulu alone accounts for 93% of Hawaii's indexed trials (405 of 437), with ‘Aiea a distant second at 27.
Phase mix: 137 Phase 3 vs 111 Phase 2 (balanced across stages).
Top condition: HIV Infections (30 trials); top sponsor Eli Lilly and Company (28).
thin-volume · low-open figures (437 trials · 26% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Hawaii on open-enrollment share
Cross-state peers under the open-share low read (thin-volume · low-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- New Hampshire · 471 trials · 33% recruiting
- Maine · 315 trials · 23% recruiting
- New Mexico · 579 trials · 29% recruiting
- West Virginia · 277 trials · 36% recruiting
- South Dakota · 273 trials · 31% recruiting
Similar low-open peers (± trial volume)
- Alaska · 25% recruiting · 485 trials
- Idaho · 26% recruiting · 633 trials
- Nevada · 27% recruiting · 900 trials
- Mississippi · 27% recruiting · 500 trials
- Louisiana · 28% recruiting · 1,936 trials